Small molecule inhibitors of IκB kinase signaling inhibit osteoclast formation in vitro and prevent ovariectomy-induced bone loss in vivo

Aymen I. Idris, Maala Krishnan, Petra Simic, Euphemie Landao-Bassonga, Patrick Mollat, Slobodan Vukicevic, Stuart H. Ralston

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The NFκB pathway plays a critical role in the regulation of osteoclast activity, and activation of the pathway is dependent on IκB kinase (IKK), which phosphorylates IκB, targeting it for proteasomal degradation. Pharmacological inhibitors of IKK exhibit anti-inflammatory properties and prevent bone erosions in models of inflammatory arthritis. However, the effects of these agents on osteoblast function and ovariectomy-induced bone loss remain unknown. Here we examined the effects of the IKK inhibitors celastrol, BMS-345541, and parthenolide on bone cell function in vitro and ovariectomy-induced bone loss in vivo. All three compounds inhibited RANKL-induced signaling in osteoclasts, caused osteoclast apoptosis, and inhibited osteoclast formation. Although parthenolide and BMS-345541 had no inhibitory effects on osteoblast function, celastrol prevented IL1β-induced TAK1 activation and inhibited osteoblast growth, differentiation, and bone nodule formation. The selective IKK inhibitors parthenolide and BMS-345541 prevented ovariectomy-induced bone loss by inhibiting osteoclastic bone resorption. We conclude that pharmacological inhibitors of IKK inhibit several critical signaling pathways in osteoclasts necessary for cell survival, formation, and activity in vitro and bone loss in vivo. Accordingly, IKK inhibitors may be of value in the prevention and treatment of bone diseases characterized by increased bone loss such as postmenopausal osteoporosis.

Original languageEnglish
Pages (from-to)4545-4555
Number of pages11
JournalFASEB Journal
Volume24
Issue number11
DOIs
Publication statusPublished - 1 Nov 2010
Externally publishedYes

Fingerprint

Ovariectomy
Osteoclasts
Bone
Phosphotransferases
Bone and Bones
Molecules
Osteoblasts
Bone Resorption
Pharmacology
Postmenopausal Osteoporosis
Critical Pathways
Bone Diseases
Osteogenesis
Chemical activation
Arthritis
In Vitro Techniques
Cell Survival
Anti-Inflammatory Agents
Apoptosis
Corrosion inhibitors

Cite this

Idris, Aymen I. ; Krishnan, Maala ; Simic, Petra ; Landao-Bassonga, Euphemie ; Mollat, Patrick ; Vukicevic, Slobodan ; Ralston, Stuart H. / Small molecule inhibitors of IκB kinase signaling inhibit osteoclast formation in vitro and prevent ovariectomy-induced bone loss in vivo. In: FASEB Journal. 2010 ; Vol. 24, No. 11. pp. 4545-4555.
@article{3496265ff43a4f249f267d51c30ee811,
title = "Small molecule inhibitors of IκB kinase signaling inhibit osteoclast formation in vitro and prevent ovariectomy-induced bone loss in vivo",
abstract = "The NFκB pathway plays a critical role in the regulation of osteoclast activity, and activation of the pathway is dependent on IκB kinase (IKK), which phosphorylates IκB, targeting it for proteasomal degradation. Pharmacological inhibitors of IKK exhibit anti-inflammatory properties and prevent bone erosions in models of inflammatory arthritis. However, the effects of these agents on osteoblast function and ovariectomy-induced bone loss remain unknown. Here we examined the effects of the IKK inhibitors celastrol, BMS-345541, and parthenolide on bone cell function in vitro and ovariectomy-induced bone loss in vivo. All three compounds inhibited RANKL-induced signaling in osteoclasts, caused osteoclast apoptosis, and inhibited osteoclast formation. Although parthenolide and BMS-345541 had no inhibitory effects on osteoblast function, celastrol prevented IL1β-induced TAK1 activation and inhibited osteoblast growth, differentiation, and bone nodule formation. The selective IKK inhibitors parthenolide and BMS-345541 prevented ovariectomy-induced bone loss by inhibiting osteoclastic bone resorption. We conclude that pharmacological inhibitors of IKK inhibit several critical signaling pathways in osteoclasts necessary for cell survival, formation, and activity in vitro and bone loss in vivo. Accordingly, IKK inhibitors may be of value in the prevention and treatment of bone diseases characterized by increased bone loss such as postmenopausal osteoporosis.",
keywords = "IKK, NFκB, Osteoblast, Osteoporosis, TAK1",
author = "Idris, {Aymen I.} and Maala Krishnan and Petra Simic and Euphemie Landao-Bassonga and Patrick Mollat and Slobodan Vukicevic and Ralston, {Stuart H.}",
year = "2010",
month = "11",
day = "1",
doi = "10.1096/fj.10-164095",
language = "English",
volume = "24",
pages = "4545--4555",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "Federation Amer Soc Exp Biol",
number = "11",

}

Small molecule inhibitors of IκB kinase signaling inhibit osteoclast formation in vitro and prevent ovariectomy-induced bone loss in vivo. / Idris, Aymen I.; Krishnan, Maala; Simic, Petra; Landao-Bassonga, Euphemie; Mollat, Patrick; Vukicevic, Slobodan; Ralston, Stuart H.

In: FASEB Journal, Vol. 24, No. 11, 01.11.2010, p. 4545-4555.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Small molecule inhibitors of IκB kinase signaling inhibit osteoclast formation in vitro and prevent ovariectomy-induced bone loss in vivo

AU - Idris, Aymen I.

AU - Krishnan, Maala

AU - Simic, Petra

AU - Landao-Bassonga, Euphemie

AU - Mollat, Patrick

AU - Vukicevic, Slobodan

AU - Ralston, Stuart H.

PY - 2010/11/1

Y1 - 2010/11/1

N2 - The NFκB pathway plays a critical role in the regulation of osteoclast activity, and activation of the pathway is dependent on IκB kinase (IKK), which phosphorylates IκB, targeting it for proteasomal degradation. Pharmacological inhibitors of IKK exhibit anti-inflammatory properties and prevent bone erosions in models of inflammatory arthritis. However, the effects of these agents on osteoblast function and ovariectomy-induced bone loss remain unknown. Here we examined the effects of the IKK inhibitors celastrol, BMS-345541, and parthenolide on bone cell function in vitro and ovariectomy-induced bone loss in vivo. All three compounds inhibited RANKL-induced signaling in osteoclasts, caused osteoclast apoptosis, and inhibited osteoclast formation. Although parthenolide and BMS-345541 had no inhibitory effects on osteoblast function, celastrol prevented IL1β-induced TAK1 activation and inhibited osteoblast growth, differentiation, and bone nodule formation. The selective IKK inhibitors parthenolide and BMS-345541 prevented ovariectomy-induced bone loss by inhibiting osteoclastic bone resorption. We conclude that pharmacological inhibitors of IKK inhibit several critical signaling pathways in osteoclasts necessary for cell survival, formation, and activity in vitro and bone loss in vivo. Accordingly, IKK inhibitors may be of value in the prevention and treatment of bone diseases characterized by increased bone loss such as postmenopausal osteoporosis.

AB - The NFκB pathway plays a critical role in the regulation of osteoclast activity, and activation of the pathway is dependent on IκB kinase (IKK), which phosphorylates IκB, targeting it for proteasomal degradation. Pharmacological inhibitors of IKK exhibit anti-inflammatory properties and prevent bone erosions in models of inflammatory arthritis. However, the effects of these agents on osteoblast function and ovariectomy-induced bone loss remain unknown. Here we examined the effects of the IKK inhibitors celastrol, BMS-345541, and parthenolide on bone cell function in vitro and ovariectomy-induced bone loss in vivo. All three compounds inhibited RANKL-induced signaling in osteoclasts, caused osteoclast apoptosis, and inhibited osteoclast formation. Although parthenolide and BMS-345541 had no inhibitory effects on osteoblast function, celastrol prevented IL1β-induced TAK1 activation and inhibited osteoblast growth, differentiation, and bone nodule formation. The selective IKK inhibitors parthenolide and BMS-345541 prevented ovariectomy-induced bone loss by inhibiting osteoclastic bone resorption. We conclude that pharmacological inhibitors of IKK inhibit several critical signaling pathways in osteoclasts necessary for cell survival, formation, and activity in vitro and bone loss in vivo. Accordingly, IKK inhibitors may be of value in the prevention and treatment of bone diseases characterized by increased bone loss such as postmenopausal osteoporosis.

KW - IKK

KW - NFκB

KW - Osteoblast

KW - Osteoporosis

KW - TAK1

UR - http://www.scopus.com/inward/record.url?scp=78649853549&partnerID=8YFLogxK

U2 - 10.1096/fj.10-164095

DO - 10.1096/fj.10-164095

M3 - Article

VL - 24

SP - 4545

EP - 4555

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 11

ER -